RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shandong Luoxin Pharma signed a $68 million agreement to acquire greater China rights to Trulance® (plecanatide) from Synergy Pharma of the US. Trulance treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. Luoxin will make a $12 million upfront payment and will be responsible for an additional $56 million of regulatory and sales milestones, plus royalties. In China, Luoxin offers products for needs in the gastrointestinal, respiratory, cardiovascular, infectious and cancer disease sectors.
Source: China Biotoday
